지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 352 - 363 (12page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomized to receive a new treatment (ETV+TDF, n=45) or maintained on the same treatment (LAM/LdT+ADV, n=46) for 48 weeks. Patients with baseline ADV resistance were excluded. Results: Compared to LAM/LdT+ADV group, ETV+TDF group had more patients with a virologic response (42/45 [93.33%] vs. 3/46 [6.52%], P<0.001) and had a greater mean reduction in serum HBV DNA level from baseline (-4.16 vs. -0.37 log10 IU/mL, P<0.001). Multivariate analysis indicated that high baseline HBV DNA level (P=0.005) and LAM/LdT+ADV maintenance therapy (P=0.001) were negatively associated with virologic response. At week 48, additional ADV- or ETVassociated mutations were cleared in ETV+TDF group, but such mutations were present in 4.3% of patients in LAM/ LdT+ADV group (P=0.106). The two groups had similar rates of adverse events. Conclusions: ETV+TDF combination treatment led to a significantly higher rate of virologic response compared to LAM/ LdT+ADV combination treatment in patients with LAM-resistant HBV who had suboptimal responses to LAM/LdT+ADV regardless of HBV genotypic resistance profile (NCT01597934).
목차
등록된 정보가 없습니다.
참고문헌 (38)
참고문헌 신청
Chen CJ / 2006 / Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level / JAMA 295:65~73
Iloeje UH / 2006 / Predicting cirrhosis risk based on the level of circulating hepatitis B viral load / Gastroenterology 130:678~686
European Association For The Study Of The Liver / 2009 / EASL clinical practice guidelines: management of chronic hepatitis B / J Hepatol 50:227~242
Liaw YF / 2008 / Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2008 update / Hepatol Int 2:263~283
Lok AS / 2009 / Chronic hepatitis B : update 2009 / Hepatology 50:661~662
Iloeje UH / 2006 / Predicting cirrhosis risk based on the level of circulating hepatitis B viral load / Gastroenterology 130:678~686
European Association For The Study Of The Liver / 2009 / EASL clinical practice guidelines: management of chronic hepatitis B / J Hepatol 50:227~242
Liaw YF / 2008 / Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2008 update / Hepatol Int 2:263~283
Lok AS / 2009 / Chronic hepatitis B : update 2009 / Hepatology 50:661~662
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
Clinical and Molecular Hepatology
2015 .01
-
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
Clinical and Molecular Hepatology
2016 .01
-
Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine- Resistant Chronic Hepatitis B
Gut and Liver
2015 .01
-
Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
Yonsei Medical Journal
2017 .01
-
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
Clinical and Molecular Hepatology
2017 .01
-
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
Clinical and Molecular Hepatology
2016 .01
-
Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study
Gut and Liver
2017 .01
-
Impact of Lamivudine Experience on the Antiviral Efficacy and Resistance Development of Entecavir in Chronic Hepatitis B Patients
Clinical and Molecular Hepatology
2015 .01
-
Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
Clinical and Molecular Hepatology
2017 .01
-
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
Clinical and Molecular Hepatology
2016 .01
-
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B
Gut and Liver
2020 .01
-
The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy
Clinical and Molecular Hepatology
2016 .01
-
Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification
Yonsei Medical Journal
2018 .01
-
Efficacy of prolonged entecavir monotherapy for partial virologic response to entecavir in treatment-naïve chronic hepatitis B patients
Clinical and Molecular Hepatology
2015 .01
-
Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
Clinical and Molecular Hepatology
2017 .01
-
Characteristics of Adenovirus Pneumonia in Korean Military Personnel, 2012–2016
Journal of Korean Medical Science
2017 .01
-
Management of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver
2017 .01
-
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
Gut and Liver
2020 .01
-
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver
2017 .01
-
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)idenaïve patients
Clinical and Molecular Hepatology
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0